Table 3.

Results from case-case analysis of association between ALL risk alleles and DS status

SNPPosGeneDS-ALL CCRLP comparison* (567 DS-ALL, 3083 non-DS ALL)DS-ALL COG comparison (255 DS-ALL, 2387 non-DS ALL)DS-ALL COG molecular subgroup adjusted comparison (255 DS-ALL, 2387 non-DS ALL)
OR (95% CI)POR (95% CI)POR (95% CI)P
rs11978267 Chr7:50466304 IKZF1 1.18 (1.03-1.36) .015 1.15 (0.95-1.39) .154 0.97 (0.77-1.23) .820 
rs3731249 Chr9:21970916 CDKN2A 1.58 (1.23-2.03) 4.08e-4 1.80 (1.27-2.55) .001 1.72 (1.10-2.69) .017 
rs3824662 Chr10:8104208 GATA3 1.34 (1.16-1.54) 4.38e-5 1.34 (1.09-1.64) .006 0.81 (0.63-1.06) .121 
rs12769953 Chr10:22407656 BMI1 1.17 (0.98-1.39) .077 1.12 (0.88-1.43) .343 1.12 (0.83-1.50) .461 
rs10741006 Chr10:22856019 PIP4K2A 1.15 (0.99-1.34) .074 1.04 (0.85-1.28) .691 0.96 (0.75-1.23) .759 
rs7089424 Chr10:63752159 ARID5B 0.98 (0.85-1.11) .71 0.77 (0.64-0.93) .006 0.80 (0.64-1.01) .056 
rs2239633 Chr14:23589057 CEBPE 1.15 (1.01-1.32) .043 1.15 (0.94-1.40) .167 1.17 (0.92-1.47) .199 
SNPPosGeneDS-ALL CCRLP comparison* (567 DS-ALL, 3083 non-DS ALL)DS-ALL COG comparison (255 DS-ALL, 2387 non-DS ALL)DS-ALL COG molecular subgroup adjusted comparison (255 DS-ALL, 2387 non-DS ALL)
OR (95% CI)POR (95% CI)POR (95% CI)P
rs11978267 Chr7:50466304 IKZF1 1.18 (1.03-1.36) .015 1.15 (0.95-1.39) .154 0.97 (0.77-1.23) .820 
rs3731249 Chr9:21970916 CDKN2A 1.58 (1.23-2.03) 4.08e-4 1.80 (1.27-2.55) .001 1.72 (1.10-2.69) .017 
rs3824662 Chr10:8104208 GATA3 1.34 (1.16-1.54) 4.38e-5 1.34 (1.09-1.64) .006 0.81 (0.63-1.06) .121 
rs12769953 Chr10:22407656 BMI1 1.17 (0.98-1.39) .077 1.12 (0.88-1.43) .343 1.12 (0.83-1.50) .461 
rs10741006 Chr10:22856019 PIP4K2A 1.15 (0.99-1.34) .074 1.04 (0.85-1.28) .691 0.96 (0.75-1.23) .759 
rs7089424 Chr10:63752159 ARID5B 0.98 (0.85-1.11) .71 0.77 (0.64-0.93) .006 0.80 (0.64-1.01) .056 
rs2239633 Chr14:23589057 CEBPE 1.15 (1.01-1.32) .043 1.15 (0.94-1.40) .167 1.17 (0.92-1.47) .199 
*

Meta-analysis of European (364 DS-ALL, 1154 non-DS ALL) and Hispanic (203 DS-ALL, 1929 non-DS ALL) ALL cases.

Analysis adjusted for top 5 principal components.

Analysis adjusted for top 5 principal components and molecular subgroups (CRLF2 high, high hyperdiploidy, ETV6-RUNX1, and B other).

or Create an Account

Close Modal
Close Modal